Preventing Lung Cancer through Tobacco Cessation at FDNY
纽约消防局通过戒烟预防肺癌
基本信息
- 批准号:10748119
- 负责人:
- 金额:$ 25.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
Quitting smoking at any age can have significant health benefits which extend beyond its well-recognized
impact on cancer. The Fire Department of the City of New York (FDNY) World Trade Center Health Program
(WTCHP) is situated within its occupational health clinics. All participants in the FDNY WTCHP low dose
computed tomography (LDCT) lung cancer screening program have access to a free, tobacco cessation
program (typically cessation counseling plus nicotine replacement treatment). While many are now former
smokers, 36% of LDCT program participants continue to smoke. Novel strategies are needed to engage
WTCHP members who continue to smoke into evidence-based smoking cessation treatment. In the proposed
trial, participants in the FDNY WTCHP LDCT screening program who are retired from FDNY will be
randomized to receive Standard Care: a letter with information about LDCT screening and the free FDNY
Tobacco Cessation program including varenicline treatment and cessation counselling via telemedicine or
Enhanced Care: a letter informing them that they will be enrolled in the FDNY Tobacco Cessation Program
unless they opt-out, similar access to varenicline treatment, but coupled with individually-tailored telemedicine
sessions with our tobacco treatment specialist using that person’s most recent LDCT results to personalize
cessation messaging. All participants will receive varenicline “preloading,” i.e., four weeks of treatment prior to
their target quit date followed by 12 weeks of treatment, an approach shown to decrease pre-quit tobacco-
associated reward. Each of the essential elements of this Enhanced Care method: opt-out enrollment and
individually-tailored biofeedback linked to LDCT results has been shown to be effective in other settings.1-5 This
protocol is the first to combine these elements plus varenicline treatment with preloading in a randomized trial
of high-risk smokers (defined as those meeting LDCT screening criteria plus WTC exposure) who have either
not enrolled in tobacco cessation or not succeeded in previous quit attempts under Standard Care. We
hypothesize that the FDNY Enhanced Care Program will be associated with both increased enrollment and
improved rates of tobacco treatment outcomes compared with Standard Care.
Specific Aim 1: To compare enrollment (participation in a first visit with our tobacco treatment specialist) in the
FDNY Tobacco Cessation Program by Standard Care vs. Enhanced Care methods.
Specific aim 1a: To evaluate demographic and clinical characteristics associated with FDNY Tobacco
Cessation Program enrollment.
Specific Aim 2: To compare outcomes (retention to study end-date, varenicline and counseling adherence and
tobacco quit rates) in the FDNY Tobacco Cessation Program by Standard Care vs. Enhanced Care methods.
Specific Aim 2a: To evaluate demographic and clinical characteristics associated with tobacco
treatment outcomes.
项目总结/摘要
在任何年龄戒烟都可以带来显着的健康益处,这些益处超出了公认的
对癌症的影响。纽约市消防局(FDNY)世界贸易中心健康计划
(WTCHP)位于其职业健康诊所内。FDNY WTCHP低剂量组的所有受试者
计算机断层扫描(LDCT)肺癌筛查计划获得免费的,戒烟
计划(通常是戒烟咨询加尼古丁替代治疗)。虽然许多人现在是前
吸烟者中,36%的LDCT计划参与者继续吸烟。需要新的战略来参与
WTCHP成员谁继续吸烟纳入循证戒烟治疗。拟议
试验中,从纽约消防局退休的纽约消防局WTCHP LDCT筛查项目参与者将
随机接受标准治疗:一封关于LDCT筛查和免费FDNY信息的信件
戒烟计划,包括伐尼克兰治疗和通过远程医疗提供戒烟咨询,
加强护理:一封信,通知他们将参加纽约消防局戒烟计划
除非他们选择退出,否则可以获得类似的伐尼克兰治疗,但同时提供个性化的远程医疗
与我们的烟草治疗专家进行的会议,使用该人最近的LDCT结果来个性化
戒烟信息。所有参与者将接受伐尼克兰“预负荷”,即,治疗前四周
他们的目标戒烟日期,然后是12周的治疗,这种方法被证明可以减少戒烟前的烟草,
相关奖励这种增强型护理方法的每个基本要素:选择退出登记和
与LDCT结果相关的个体定制生物反馈已被证明在其他环境中有效。
该方案是第一个在随机试验中联合收割机将这些元素与伐尼克兰治疗结合预负荷的方案
高风险吸烟者(定义为符合LDCT筛查标准加上WTC暴露的人),
未参加戒烟或在标准治疗下既往戒烟尝试未成功。我们
我假设纽约消防局加强护理计划将与增加的入组人数和
与标准治疗相比,烟草治疗结果的改善率。
具体目标1:比较两组的入组情况(参加我们的烟草治疗专家的首次访视),
FDNY标准护理与增强护理方法的戒烟计划。
具体目标1a:评价FDNY烟草相关的人口统计学和临床特征
停止计划注册。
具体目标2:比较结果(保留至研究结束日期、伐尼克兰和咨询依从性以及
通过标准护理与增强护理方法,在FDNY戒烟计划中观察到的戒烟率。
具体目标2a:评价与烟草相关的人口统计学和临床特征
治疗结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shadi Nahvi其他文献
Shadi Nahvi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shadi Nahvi', 18)}}的其他基金
Mentoring investigators to improve health outcomes among persons with opioid and tobacco use disorder
指导研究人员改善阿片类药物和烟草使用障碍患者的健康结果
- 批准号:
10591521 - 财政年份:2022
- 资助金额:
$ 25.87万 - 项目类别:
Mentoring investigators to improve health outcomes among persons with opioid and tobacco use disorder
指导研究人员改善阿片类药物和烟草使用障碍患者的健康结果
- 批准号:
10449868 - 财政年份:2022
- 资助金额:
$ 25.87万 - 项目类别:
Achieving smoking cessation milestones in opioid treatment patients: a randomized 2 x 2 factorial trial of directly observed and long-term varenicline
在阿片类药物治疗患者中实现戒烟里程碑:直接观察和长期伐尼克兰的随机 2 x 2 析因试验
- 批准号:
9634050 - 财政年份:2017
- 资助金额:
$ 25.87万 - 项目类别:
Achieving smoking cessation milestones in opioid treatment patients: a randomized 2 x 2 factorial trial of directly observed and long-term varenicline
在阿片类药物治疗患者中实现戒烟里程碑:直接观察和长期伐尼克兰的随机 2 x 2 析因试验
- 批准号:
10302312 - 财政年份:2017
- 资助金额:
$ 25.87万 - 项目类别:
Achieving smoking cessation milestones in opioid treatment patients: a randomized 2 x 2 factorial trial of directly observed and long-term varenicline
在阿片类药物治疗患者中实现戒烟里程碑:直接观察和长期伐尼克兰的随机 2 x 2 析因试验
- 批准号:
10063497 - 财政年份:2017
- 资助金额:
$ 25.87万 - 项目类别:
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
美沙酮维持治疗患者的伐尼克兰戒烟治疗
- 批准号:
8517633 - 财政年份:2010
- 资助金额:
$ 25.87万 - 项目类别:
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
美沙酮维持治疗患者的伐尼克兰戒烟治疗
- 批准号:
8048522 - 财政年份:2010
- 资助金额:
$ 25.87万 - 项目类别:
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
美沙酮维持治疗患者的伐尼克兰戒烟治疗
- 批准号:
8146151 - 财政年份:2010
- 资助金额:
$ 25.87万 - 项目类别:
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
美沙酮维持治疗患者的伐尼克兰戒烟治疗
- 批准号:
9183509 - 财政年份:2010
- 资助金额:
$ 25.87万 - 项目类别:
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
美沙酮维持治疗患者的伐尼克兰戒烟治疗
- 批准号:
8704907 - 财政年份:2010
- 资助金额:
$ 25.87万 - 项目类别:
相似国自然基金
胚胎脑发育的分子机理:lgl2(late gestation lung 2)蛋白质的生物学功能的研究
- 批准号:30470854
- 批准年份:2004
- 资助金额:18.0 万元
- 项目类别:面上项目
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 25.87万 - 项目类别:
人口知能を用いたCT画像に基づくLung Cancer mimicking Organizing Pneumonia の診断
利用人工智能基于CT图像模拟组织性肺炎的肺癌诊断
- 批准号:
24K18841 - 财政年份:2024
- 资助金额:
$ 25.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Epigenomic Methods to Improve Personalised Treatment in Patients with Lung Cancer and Malignant Pleural Effusion.
表观基因组方法改善肺癌和恶性胸腔积液患者的个体化治疗。
- 批准号:
MR/X030938/1 - 财政年份:2024
- 资助金额:
$ 25.87万 - 项目类别:
Research Grant
Living in limbo: The Experience of and Relationship between Fear of Progression, Illness Uncertainty, Symptom Burden, and Death Anxiety in Patients with Advanced or Metastatic Lung Cancer Receiving Immunotherapy or Targeted Therapy
生活在不确定之中:接受免疫治疗或靶向治疗的晚期或转移性肺癌患者对病情进展的恐惧、疾病的不确定性、症状负担和死亡焦虑的经历和关系
- 批准号:
478587 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Operating Grants
Advanced Raman Spectroscopy for Exhaled Breath Analysis for Lung Cancer Detection
用于肺癌检测的呼出气体分析的先进拉曼光谱
- 批准号:
494958 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Operating Grants
Lung cancer therapy using genetically modified macrophages
使用转基因巨噬细胞治疗肺癌
- 批准号:
488420 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Operating Grants
Study of the mechanisms of lung cancer development through multi-omics analysis of normal tissues and precancerous lesions of the lung
通过肺部正常组织和癌前病变的多组学分析研究肺癌发生的机制
- 批准号:
23H02758 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of a novel therapeutic strategy targeting the microenvironment that tolerates the progression of refractory lung cancer
开发针对难治性肺癌进展的微环境的新型治疗策略
- 批准号:
23H02996 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of highly accurate diagnostic method using photodynamic diagnosis of aminolevulinic acid for lung cancer pleural disseminated lesions
氨基乙酰丙酸光动力诊断肺癌胸膜播散性病变高精度诊断方法的开发
- 批准号:
23K08286 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a new lung cancer therapy targeting a MAML3-Hh/NOTCH signaling pathway
开发针对 MAML3-Hh/NOTCH 信号通路的新型肺癌疗法
- 批准号:
23K08298 - 财政年份:2023
- 资助金额:
$ 25.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




